ImmunityBio (IBRX) Draws Fresh Attention, Is The Stock Still Undervalued?
Nant Capital’s plan to invest up to $22.3 million in a PIPE deal with PDS Biotech, along with Patrick Soon Shiong’s new board role there, has put ImmunityBio (IBRX) firmly back in focus for investors.
For ImmunityBio, the renewed attention comes on top of very strong recent performance, with the share price at US$8.46 and a 1-day share price return of 6.95% feeding into a 90-day gain of 14.95%. The year-to-date share price return of 318.81% and 1-year total shareholder return of 196.84% show that momentum has been building over a longer stretch, even though the 5-year total shareholder return has declined 21.01%.
Scan beyond ImmunityBio and see how other high-potential biotech and healthcare names stack up in our hand picked list of 16 high quality undiscovered gems.
ImmunityBio now carries a multibillion dollar valuation and a share price that has moved sharply higher in 2026. The key tension for investors is simple: Does the current price still fairly reflect the underlying business?
Most Popular Narrative: 35% Undervalued
ImmunityBio’s most followed valuation storyline pegs fair value at $13, which sits well above the recent $8.46 close and puts a spotlight on how much faith investors place in its pipeline and commercial ramp.
The analysts have a consensus price target of $13.0 for ImmunityBio based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $15.0, and the most bearish reporting a price target of just $12.0.
See why 14 investors see ImmunityBio as 35% undervalued.
This narrative framework uses a 7.4% discount rate and a $13 fair value to argue that the current share price reflects a sizeable gap to the level implied by those long range revenue and margin assumptions.
Result: Fair Value of $13 (UNDERVALUED)
Still, the ImmunityBio story can change quickly if ANKTIVA trials in new settings disappoint or if regulators take a tougher line on additional approvals.
Find out about the key risks to this ImmunityBio narrative.
Next Steps
Mixed about the ImmunityBio story after all of this. Act quickly, pull up the data, and stress test both sides of the argument with 3 key rewards and 1 important warning sign.
Looking for more ImmunityBio investment ideas?
Do not stop with ImmunityBio. Broaden your watchlist with targeted stock ideas that match how you like to manage risk, income, and upside potential.
- Chase higher upside potential in smaller companies by scanning 7 elite penny stocks with strong financials that already show stronger financial underpinnings.
- Zero in on quality at a discount and use the 29 high quality undervalued stocks to spot opportunities where fundamentals and price still look out of sync.
- Build a portfolio that can pay you while you wait by checking the 6 dividend fortresses focused on robust income streams.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com